

## II. REMARKS

Claim 1 has been amended herein for clarity. This amendment does not introduce new matter.


## III. SUMMARY

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 391442004300. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: September 14, 2001

By:


  
Laurie A. Axford  
Registration No. 35,053

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5133  
Facsimile: (858) 720-5125

Version with markings to show changes made

Please amend Claim 1 as follows:

1. (Amended) A *cis*-platinum complex of the formula Ia or Ib



or a pharmaceutically acceptable salt thereof

wherein:

each A is independently an anion;

each B is independently halo, hydroxy, carboxylate, carbamate or a carbonate ester,

Z is a substituted 5- or 6-membered, heterocyclic moiety, wherein the substituted heterocyclic moiety further comprises a [wherein at least one] substituent that sterically hinders access of the Pt atom to a DNA strand of a tumor cell by a measurable amount more than an unsubstituted heterocyclic moiety with the same structure when tested under the same conditions, and wherein Z is other than pyridine; and

X is NH<sub>3</sub> or mono- or dialkyl substituted NH<sub>3</sub>.